Nalmefene Consta/Vanoxerine Consta - Kadric, Sead;Mohler, Hanns;Kallioniemi, Olli
26,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

"Long-acting depot formulations of Nalmefene: Nalmefene Consta 393.1 mg, novel treatment for opioid dependence." Efficacy and tolerability of a long-acting intramuscular formulation of Nalmefene (Nalmefene Consta 393.1 mg, Aurum Phrmaceuticals) for treatment of opioid-dependent patients. "Long-acting depot formulations of Vanoxerine: Vanoxerine Consta 394.2 mg, novel treatment for cocaine dependence." Efficacy and tolerability of a long-acting intramuscular formulation of Vanoxerine (Vanoxerine Consta 394.2 mg, Aurum Phrmaceuticals) for treatment of cocaine-dependent patients.

Andere Kunden interessierten sich auch für
Produktbeschreibung
"Long-acting depot formulations of Nalmefene: Nalmefene Consta 393.1 mg, novel treatment for opioid dependence." Efficacy and tolerability of a long-acting intramuscular formulation of Nalmefene (Nalmefene Consta 393.1 mg, Aurum Phrmaceuticals) for treatment of opioid-dependent patients. "Long-acting depot formulations of Vanoxerine: Vanoxerine Consta 394.2 mg, novel treatment for cocaine dependence." Efficacy and tolerability of a long-acting intramuscular formulation of Vanoxerine (Vanoxerine Consta 394.2 mg, Aurum Phrmaceuticals) for treatment of cocaine-dependent patients.
Autorenporträt
Kadric, Sead
Born in Bosnia and Herzegovina, Tuzla, 1963. Lives and works in London since 1991. Clinical director at Priory Hospital Roehampton. Postgraduate Researcher at King's College London (Psychiatry Research with Neuroscience). Director of Adolescent Addiction Programs at the Department of psychiatry at Harvard Medical School and visiting professor.